Attention! An update has been made to the content of this web page.
AmeriHealth is pleased to announce that infliximab (Remicade®) is now able to be administered at Walgreens infusion suites for AmeriHealth members who are approved to receive this drug.
Over the next few months Walgreens will reach out to select network physicians whose patients typically receive Remicade® in an outpatient facility setting. As part of the discussions, they will offer information about the Walgreens Site of Care Optimization Program, highlighting the benefits of administering Remicade® in Walgreens infusion suites.
Another option for physicians whose patients typically receive Remicade® in an outpatient facility setting is to have it administered by an AmeriHealth-approved home infusion provider. Home infusion providers are medical professionals who bring drugs and medical supplies to the member?s home, monitor the member during the infusion, and remove all used supplies after the infusion is complete. Many members choose home infusion therapy because they can coordinate their treatment based on their schedule and receive treatment in the comfort and convenience of their own home.
In most cases, members who choose to receive drug therapy in an infusion suite or through home infusion pay lower cost-sharing amounts (i.e., copayment, deductible, coinsurance) than members who receive drug therapy in an outpatient facility setting.
To learn more about options for the administration of Remicade® in an infusion suite or the member?s home, please call Customer Service at 1-800-275-2583 for providers in Pennsylvania and Delaware and at 1-888-YOUR-AH1 (1-888-968-7241) for providers in New Jersey.
Note: Janssen Biologics, Inc. and Walgreens are conducting separate outreach to providers on the use of Remicade®.